MEK 1 inhibition and bleeding in hereditary haemorrhagic telangiectasia

Br J Haematol. 2024 Jan;204(1):361-365. doi: 10.1111/bjh.19167. Epub 2023 Oct 23.

Authors

Claire L Shovlin^{1

2

3}, Dilip Patel^{1

2}, Adrianna Bielowka^{1

2}, Jonathan A Ledermann⁴, Atieh Modarresi¹; Genomics England Research Consortium⁵; Maria E Bernabeu-Herrero^{1

2}, Micheala A Aldred⁶, Ali Alsafi³

Affiliations

¹ National Heart and Lung Institute, Imperial College London, London, UK.
² NIHR Imperial Biomedical Research Centre, London, UK.
³ Imperial College Healthcare NHS Trust, London, UK.
⁴ Department of Oncology, University College London Cancer Institute, London, UK.
⁵ Genomics England, London, UK.
⁶ Indiana University School of Medicine, Indianapolis, Indiana, USA.

PMID: 37872650
DOI: 10.1111/bjh.19167

No abstract available

Publication types

Letter
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't

MeSH terms

Epistaxis
Hemorrhage / etiology
Humans
Mitogen-Activated Protein Kinase Kinases
Telangiectasia, Hereditary Hemorrhagic* / complications
Treatment Outcome

Substances

Mitogen-Activated Protein Kinase Kinases

Grants and funding